Format

Send to

Choose Destination
See comment in PubMed Commons below
FEBS Lett. 2007 Dec 11;581(29):5664-70. Epub 2007 Nov 20.

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.

Author information

1
Life Science and Bioethics Research Center, Tokyo Medical and Dental University, Tokyo, Japan.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome characterized by dislipidemia and insulin resistance. We hypothesized that ezetimibe, an inhibitor of NPC1L1, improves these metabolic disorders in Zucker obese fatty rats (ZOF). Ezetimibe significantly lowered total cholesterol and triglycerides in ZOF with prominent reduction in the remnant lipoprotein fraction and small dense low density lipoprotein fraction. Moreover, lipid deposition and fibrosis of liver were decreased by ezetimibe. Interestingly, ezetimibe improved insulin and plasma glucose response after intraperitoneal glucose injection. Further, ezetimibe enhanced insulin signaling in cultured hepatocytes. Our results indicate the potential of ezetimibe in treating the metabolic syndrome and NAFLD.

PMID:
18022391
DOI:
10.1016/j.febslet.2007.11.023
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center